JP2013526518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526518A5 JP2013526518A5 JP2013510067A JP2013510067A JP2013526518A5 JP 2013526518 A5 JP2013526518 A5 JP 2013526518A5 JP 2013510067 A JP2013510067 A JP 2013510067A JP 2013510067 A JP2013510067 A JP 2013510067A JP 2013526518 A5 JP2013526518 A5 JP 2013526518A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nifedipine
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(NC(C)=C(C1Cc(cc2*)cc(*)c2Oc(cc2*)cc(*)c2O)C(OC)=O)=C1C(OC)=O Chemical compound CC(NC(C)=C(C1Cc(cc2*)cc(*)c2Oc(cc2*)cc(*)c2O)C(OC)=O)=C1C(OC)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/034721 WO2010132671A1 (en) | 2009-05-15 | 2010-05-13 | Treatment of mci and alzheimer's disease |
| USPCT/US2010/034721 | 2010-05-13 | ||
| PCT/US2010/057287 WO2011142778A1 (en) | 2010-05-13 | 2010-11-18 | Treatment of mci and alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526518A JP2013526518A (ja) | 2013-06-24 |
| JP2013526518A5 true JP2013526518A5 (https=) | 2014-01-09 |
Family
ID=44923820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510067A Pending JP2013526518A (ja) | 2010-05-13 | 2010-11-18 | Ｍｃｉおよびアルツハイマー病の処置 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2568811A4 (https=) |
| JP (1) | JP2013526518A (https=) |
| CN (1) | CN102984938A (https=) |
| AU (1) | AU2010353287A1 (https=) |
| CA (1) | CA2799162A1 (https=) |
| WO (1) | WO2011142778A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2994160T (lt) * | 2013-05-06 | 2019-08-26 | Baxalta Incorporated | Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g |
| CN111426848A (zh) | 2013-06-28 | 2020-07-17 | 株式会社 Mcbi | 认知功能障碍疾病的生物标记物及使用该生物标记物的认知功能障碍疾病的检测方法 |
| JP6276865B2 (ja) * | 2014-01-29 | 2018-02-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリールラクタムキナーゼ阻害剤 |
| CN106177046A (zh) * | 2016-08-29 | 2016-12-07 | 杨添福 | 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法 |
| CN106645505A (zh) * | 2016-11-18 | 2017-05-10 | 中国医科大学 | 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法 |
| CN107022019B (zh) * | 2016-11-24 | 2020-10-30 | 桂林医学院 | 一种用于脑内降铁除自由基的多肽、制备方法与应用 |
| CN106636388A (zh) * | 2016-12-15 | 2017-05-10 | 湖南中能荆卫生物科技有限公司 | 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用 |
| CN108191966B (zh) * | 2018-01-11 | 2020-10-27 | 桂林医学院 | 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 |
| KR20220004618A (ko) * | 2019-01-07 | 2022-01-11 | 세나 바이오사이언스 아이엔씨. | 신규한 펩티드 및 이의 용도 |
| JP7321017B2 (ja) * | 2019-07-17 | 2023-08-04 | 東海物産株式会社 | 機能性食品 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8002A (en) * | 1851-03-25 | Upright pianoforte | ||
| DE2126533A1 (de) * | 1971-05-28 | 1972-12-14 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur Herstellung pharma zeutischer Zubereitungen |
| US6558650B1 (en) * | 1998-04-08 | 2003-05-06 | Oregon Health And Science University | Enhancement of cellular gallium uptake |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| CN1479616A (zh) * | 2000-11-21 | 2004-03-03 | 霍华德・齐克 | 使用1,4-二氢吡啶钙通道阻断剂治疗疱疹神经病毒病症 |
| WO2005051389A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceuticals Corporation | Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| EP1874311B1 (en) * | 2005-04-15 | 2011-10-05 | Research & Innovation S.p.A. | A method for preventing, delaying or reverting abnormal amyloid deposition |
| US20090286879A1 (en) * | 2005-12-02 | 2009-11-19 | Kiyoshi Hashizume | Preventive or Therapeutic Drug for Alzheimer-Type Dementia |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| WO2008109613A1 (en) * | 2007-03-05 | 2008-09-12 | Wyeth | Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors |
| CA2737618A1 (en) * | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| TW201103907A (en) * | 2009-03-20 | 2011-02-01 | Lundbeck & Co As H | Amide derivatives as neuropeptide Y5 receptor ligands |
-
2010
- 2010-11-18 AU AU2010353287A patent/AU2010353287A1/en not_active Abandoned
- 2010-11-18 JP JP2013510067A patent/JP2013526518A/ja active Pending
- 2010-11-18 WO PCT/US2010/057287 patent/WO2011142778A1/en not_active Ceased
- 2010-11-18 EP EP10851531.3A patent/EP2568811A4/en not_active Withdrawn
- 2010-11-18 CN CN2010800680043A patent/CN102984938A/zh active Pending
- 2010-11-18 CA CA2799162A patent/CA2799162A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526518A5 (https=) | ||
| JP2012526844A5 (https=) | ||
| JP2013526518A (ja) | Ｍｃｉおよびアルツハイマー病の処置 | |
| US9750747B2 (en) | Treatments involving eslicarbazepine acetate or eslicarbazepine | |
| AU2013334874B2 (en) | Combination therapies for the treatment of Alzheimer's disease and related disorders | |
| JP2012526844A (ja) | Ｍｃｉおよびアルツハイマー病の処置 | |
| JP2015510941A5 (https=) | ||
| US9968574B2 (en) | Treatment of MCI and Alzheimer's disease | |
| JP2021167361A (ja) | 神経変性障害を処置するための方法 | |
| JP2010531854A5 (https=) | ||
| JP2020527172A5 (https=) | ||
| Schreiber et al. | Treatment of refractory status epilepticus in childhood | |
| CN120569199A (zh) | 普利多匹定用于治疗青少年亨廷顿病 | |
| TW202425995A (zh) | 減少與神經退化疾病相關的神經退化的方法 | |
| AU2021317186A1 (en) | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease | |
| WO2025134069A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| WO2024251159A1 (zh) | 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂 | |
| JP2016047838A (ja) | 酢酸エスリカルバゼピン及び使用方法 | |
| IL322574A (en) | Compositions and methods for treating neurodegenerative diseases | |
| Ryan | Agents I: Anti-infectives | |
| Lovell et al. | Treatment of MCI and Alzheimer's Disease | |
| Iwatani et al. | P-88 The effect of strong statins in diabetic nephropathy—comparison of atorvastatin and pitavastatin |